AC
ALXN

Avestar Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Avestar Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-781
Closed -$86K – 932
2019
Q2 		$86K Sell
781
-55
-7% -$7.09K 0.05% 225
2019
Q1 		$98K Buy
836
+81
+11% +$10.1K 0.06% 197
2018
Q4 		$53K Sell
755
-243
-24% -$28.7K 0.04% 258
2018
Q3 		$117K Buy
998
+133
+15% +$16.7K 0.07% 181
2018
Q2 		$86K Buy
865
+91
+12% +$10.6K 0.05% 215
2018
Q1 		$67K Buy
774
+160
+26% +$19.1K 0.04% 214
2017
Q4 		$58K Buy
+614
New +$74.8K 0.04% 233

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Avestar Capital's ALXN Position: Q3 2019 in Review

Avestar Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 781 shares — an estimated $86K sold.

Avestar Capital first reported a position in ALXN in Q4 2017 and held it in 7 quarters. The position peaked at $117K in Q3 2018. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Avestar Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Avestar Capital sold 781 Alexion Pharmaceuticals shares in Q3 2019, an estimated $86K.
  • Avestar Capital first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 7 quarters.
  • Avestar Capital's Alexion Pharmaceuticals position peaked at $117K in Q3 2018.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.